Chandra Thomas Whitfield is a multiple award-winning multimedia journalist whose work has appeared in a wide variety of media outlets, including NBCNews.com, The New York Times, The Washington Post, The Huffington Post, The Undefeated, Essence, Ebony, People, Newsweek, The Root, The Grio, TIME.com and the Atlanta affiliate of NPR. She is a 2019-2020 Leonard C. Goodman Institute for Investigative Journalism Fellow and host/producer of “In The Gap,” a podcast for In These Times magazine about how the gender pay gap affects the lives — and livelihoods — of Black women in America.
Chandra has also been named "Journalist of the Year" from the Atlanta Press Club and the Atlanta Association of Black Journalists and honors from the Association for Women in Communications, the Colorado Association of Black Journalists and Mental Health America. She is an alum of a diverse mix of prestigious journalism fellowships, including with the Schuster Institute for Investigative Journalism at Brandeis University, the Education Writers Association, Ted Scripps Environmental Journalism at the University of Colorado Boulder, Soros Justice Media, Kiplinger Public Affairs at the Ohio State University, the Poynter Institute for Media Studies and Rosalynn Carter Mental Health Journalism programs, respectively. A feature story that she penned for AtlantaMagazine made the Atlanta Press Club's “Atlanta’s Top 10 Favorite Stories of the Past 50 Years” list and it is also widely credited with contributing to a change in Georgia law and a teen’s early release from a 10-year prison sentence.
She has also snagged one-on-one interviews with a long list of notable newsmakers, including one of the Exonerated 5 from New York’s famed Central Park Jogger case and anti-racism educator Jane Elliott. Still, she credits being a dedicated wife and mommy as among her greatest accomplishments.
Full BioLearn about our editorial policies
Lung cancer survivor Ayanay Ferguson says she supports expanded early screening access for Black lung cancer patients. (Photo: Courtesy of Ayanay Ferguson)
Despite recent changes in screening guidelines, disparities persist for Black lung cancer patients
Ayanay Ferguson knew something just wasn’t right with her body when she returned from vacation with her husband in April 2021.
“I had swollen ankles and shortness of breath,” recalled Ferguson, 50, an Atlanta-area clinical psychologist.
She initially thought her symptoms were from post-vacation fatigue and her weight. As her symptoms lingered, she booked a telehealth appointment with a doctor, who advised her to get her heart checked. An EKG in an emergency room at a nearby hospital came back normal, but a medical resident was concerned enough about some of her lab work results to look into it further.
“He said he had just read an article about how that particular blood test did not elevate in African Americans, when there was, in fact, an issue, and that’s what kept him looking for stuff,” remembered Ferguson. “That’s why he ordered a CT chest scan.”
The CT scan showed what was later found to be a cancerous mass in her right lung. The diagnosis: stage 3Anon-small cell adenocarcinoma. “I had cancer cells in some of my lymph nodes,” she says.
Read: Understanding the Different Types of Lung Cancer >>
The lung cancer diagnosis was a shock for Ferguson, who’d never been a cigarette smoker and did not have a family history of the disease, but she agreed to the aggressive treatment plan her thoracic surgeon ordered. The plan was for her to have surgery to remove the mass and four rounds of chemotherapy. Three years later, Fergurson proudly reports being cancer-free.
A growing body of research reveals that, as a Black person, she is especially lucky to have beaten the disease that kills more than 125,000 Americans a year — more than breast, colon and prostate cancers combined. Lung cancer is more difficult to treat in its advanced stages, so early detection through screening greatly increases a person’s chance of survival. Yet racial disparities exist.
Studies have found that Black lung cancer patients were 15% less likely than white patients to be diagnosed early and they had the lowest five-year survival rate of any racial group. Black Americans tended to develop lung cancer at higher rates and at younger ages than their white counterparts, despite smoking fewer cigarettes on average. According to the American Lung Association, the disease claimed the lives of more than 14,000 Black Americans in 2021, the most recent year for available data.
Addressing persistent disparities in lung cancer early diagnosis and survival rates is central to the work being carried out by Melinda Aldrich, M.D., an associate professor at Vanderbilt University Medical Center. The groundbreaking 2019 study she co-authored with five colleagues found that screening eligibility guidelines exclude Black smokers more than other people of other races. The healthcare industry has been slow to respond to the growing push to change that, including medical insurance companies that determine what is considered preventive care and covered at low or no cost.
Aldrich’s research found that the U.S. Preventive Services Task Force (USPSTF), the government group that sets screening guidelines, required that a person had to be between 55 and 80 years old and have smoked the equivalent of a pack a day for 30 years to qualify for a life-saving early detection screening known as a low-dose CT scan. In addition to these criteria, a person needs to be either a current or former smoker, and former smokers need to have quit within the prior 15 years. Aldrich’s analysis of more than 84,000 adult smokers revealed that under that criteria, Black patients at relatively high risk of lung cancer were being disproportionately excluded from the eligible screening pool. More than 2 out of 3 Black smokers who were diagnosed with lung cancer did not meet the age and smoking history criteria at the time of their diagnosis.
“Based on those guidelines, we saw that of people who were diagnosed with lung cancer, 68% of African American individuals … would not have been eligible for lung cancer screening. And this is in contrast to 44% of white Americans who would not be eligible,” she said. “So, [there are] strong racial disparities in terms of eligibility and who’s able to get in the door to be screened.”
The work of Aldrich and her co-authors was cited in a 2021 decision by the USPSTF to make two changes that have nearly doubled the number of people eligible for lung cancer screening — lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
“They didn’t do exactly what we proposed: something that might be considered controversial, which is making a race-specific change in the guidelines,” she said. “They made the guideline changes for everyone. So, actually, the disparities remain. They just made more people eligible.”
Aldrich said raising awareness about the screening test that has been widely available for well over a decade now is critical to helping improve outcomes and survival rates for lung cancer patients, especially Black patients. Still, she said, the medical industry needs to answer the call to go a step further to allow more people to qualify for early screening based on additional risk factors, such as race and ethnicity and family history. “If you have a history of smoking, talk to your doctor about whether you’re eligible for lung screening,” advised Aldrich. “We also need to remove the stigma associated with smoking; we should unite the community rather than associating blame.”
Ferguson said that although race-specific screening guideline changes most likely would not have helped in her case as a nonsmoker, she supports the shift to expand screening eligibility. “I don’t care if you are 30 or 70. If you smoked every day for 10 years or more, you should be able to say to your doctor, ‘I want a lung cancer screening’ and get it,” she said. “It’s money spent on the front end and money saved on the back end. And more importantly, it’s going to save more lives.”
This educational resource was created with support from Merck.
